Large shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connection

Sunstone Life Science Ventures is not selling its Orphazyme shares because of the upcoming crucial FDA ruling, general partner Sten Verland tells MedWatch.

Sten Verland, General Partner at Sunstone Life Sciences and board member at Orphazyme. | Photo: Sunstone / PR

As the FDA's response deadline for Orphazyme's drug candidate arimoclomol draws ever closer, Sunstone Life Science Ventures has opted to sell some of its shares in the biotech company.

As of Friday last week, the investment company owned less than five percent of shares in Orphazyme, meaning it dropped below the large shareholder boundary, according to a stock exchange notification released on Tuesday.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs